The Differential Effects of Diabetes Therapy on Inflammation

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to determine if different diabetes treatments have different effects on inflammation; in particular, kidney inflammation. This type of inflammation is common in people with diabetes, and can lead to kidney failure. This study will investigate the effect of different types of diabetes treatment on kidney inflammation. This will help us to decide if certain types of medicine should be preferred in people with evidence of inflammation in their kidneys, as this may help prevent major complications including kidney failure.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University College Dublin
• Collaborators: Eli Lilly and Company; Irish Endocrine Society; Merck Sharp & Dohme Corp.; Royal College of Physicians
• Treatments: Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Liraglutide

Criteria

Inclusion Criteria:

• Age over 30 years

• Diagnosis of type 2 diabetes for one year or more

• Diagnosis of DKD as defined by two distinct albumin:creatinine ratio measurements above the gender specific range in the local reference laboratory with an interval of no less than eight week between measurements

• Stable dose of an inhibitor of the renin angiotensin system for a period of 8 weeks

Exclusion Criteria:

• Any cognitive impediment that preclude the participant from giving free and informed consent

• Substance abuse including alcohol excess

• Use of a GLP-1 analogue in the last 6 months

• Pregnancy

• Hypersensitivity to the prescribed treatment